Q2 2021 Aveanna Healthcare Holdings Inc Earnings Call

August 12, 2021

[music].

Good morning, and welcome to the Avianca healthcare Holdings' second quarter 2021 earnings Conference call.

Today's call is being recorded and we have allocated one hour for prepared remarks and Q&A.

At this time I'd like to turn the conference over to Shannon Drake I'll be honest, Chief legal officer and corporate Secretary. Thank you you may begin.

Thank you operator, good morning, everyone and thank you for joining all of you on our healthcare second quarter 2021 earnings call speaking on today's call are Tony Strange I'll be honest, Chief Executive Officer, and President David <unk>, Our Chief Financial Officer, and Jeff Shaner, I'll be honest Chief operating officer.

We issued our second quarter earnings press release and filed our related form 8-K, and form 10-K yesterday with the SEC. These documents are available on the Investor Relations section of our website at Ww Dot Aviano Dot com. We encourage you to read them also a replay of this call will be available on our website until August 19th 2000.

'twenty, one we want to remind anyone who may be listening to a replay of this call that all statements made are as of today August 12, 2021, and these statements have not been nor will they be updated subsequent to today's call.

Also today's call may contain forward looking statements, which may be identified by words, such as May could will expect intend plan and other similar words and expressions. All forward looking statements made today are based on management's current expectations assumptions and beliefs about our business and the environment in which we operate these statements are subject to rich.

Since the uncertainties that could cause our actual results to materially differ from those expressed or implied on today's call listeners should not plan place undue reliance on forward looking statements and are encouraged to review our SEC filings for a more complete discussion of factors that could impact our results, including those risks disclosed under the risk factor headings of our filings.

Except as required by federal Securities laws Aviano does not undertake to publicly update or revise any forward looking statements. Subsequent to the date made as a result of new information future events changing circumstances or for any other reason.

Also in addition to our financial results reported in accordance with GAAP, We supplement our GAAP results with certain non-GAAP financial measures when viewed together with our GAAP results. We believe that these measures can provide a more complete understanding of our business and operating results.

But they should not be relied upon to the exclusion of our financial results reported in accordance with GAAP. In addition, a reconciliation of any non-GAAP measure mentioned during our call to the most comparable GAAP measure is available in our earnings press release and 10-Q, both of which are available on our website and on the SEC's website at Ww Dot FCC.

Gov.

Following today's prepared remarks, we will open the call to questions. Please limit your initial comments to one question and one follow up so that we can accommodate as many callers as possible in the allotted time with that I will turn the call over to Avi honest, Chief Executive Officer, President Tony Strange Tony.

Thanks, Shannon and good morning, everyone. Thank you for joining I'll be honest second quarter earnings call before we get started I'd like to welcome our new investors and say thank you for joining the Aviano story.

For our new participants Avi on it is a highly diversified homecare platform specializing in providing both skilled and unskilled care two pediatric adult and senior patients in the most cost effective setting possible their homes. We operate in 30 states across the U S through 263 located.

<unk>, our clinical team focuses on providing exceptional position directed care to each of the 46000 patients that we serve.

It's been a busy quarter on the call today. In addition to our operating results, we'd like to provide an overview of the reimbursement environment and update on our recent financing activities and finally, the latest developments surrounding our M&A transactions in pipeline. So let's jump right into our results Q2 marks another successful.

Full quarter for Aviano as we continued to build on the momentum that we reported in Q1 revenues for the quarter were $436 million compared to 352 million in Q2 of 2020, representing a year over year increase of 24% and up sequentially.

Chile from $417 million in Q1.

Our compounded aggregated growth rate over the last three years has been in excess of 17% and we believe as is supported by our current results that maintaining growth rates in the mid to high teens continues to be sustainable.

Moving on to gross margins gross margins for the quarter were 33, 6% compared to 33% in Q2 of 2020 and up sequentially from 31, 6% in Q1 of 'twenty. One the improvements have been driven by rate improvements across our Pts segment the mix shift.

Driven by the growth in our home health and hospice segment.

And a disciplined approach to managing labor expenses.

I'm very proud of our operating teams for not only preserving but improving margins during a very difficult environment.

EBIT for the quarter was 49 million compared to $37 million in Q2 of 2020, an increase of 31% year over year.

Adjusted earnings per diluted share for the quarter was 10 cent compared to eight <unk> in Q1.

These results on top of a very good cash collections give us confidence that we can and will sustain our growth rates, while continuing to protect our margin and leveraging our infrastructure, therefore, creating significant value for our shareholders as well as our patients and our employees.

Speaking of our employees I'd like to thank all of our caregivers administrative staff and our leadership team for making these results a reality. It is your dedication to our mission that makes RV honest successful I'd also like to welcome the employees of our most recent acquisition Doctor's choice to the Aviano family.

It's great to have you on our team.

Moving on to the reimbursement environment.

Our government and payer relations teams have been working hand in hand, with our different state legislators state administrations as well as our managed care partners to protect and create new avenues for patients to receive care in the home.

The result is that over 50% of the states that we service will increase the reimbursement rate and or expand the cupboard benefit for the services that we provide.

To be specific.

We have or will receive rate increases in 16 of our covered states in 2021, Jeff will provide some additional color on these increases during his comments, but the net takeaway is that state Medicaid agencies and managed care plans alike are recognizing.

<unk> the important role that homecare can play in reducing our overall healthcare spend.

These investments into the homecare benefit will allow providers to make additional investments into caregiver wages, which should accelerate growth for the industry.

From a Medicare perspective, CMS has issued a proposed rule for home health and a final rule for hospice on the home Health front, we view the proposed rule as an overall positive for the industry. It appears that providers will experience approximately a one 7% increase to reimbursement, but equally positive.

US is the indication that CMS is moving forward with its commitment to evaluate value based pricing. There are several legislative efforts underway such as choose home.

To elevate the impact that homecare can play in helping post acute care patients transitioned back to their homes and allowing them to age in place.

We believe that the investments that we have made and are making into our clinical delivery model as well as our clinical documentations system, we are well positioned to be on the right side of value based reimbursement.

And while hospice is currently a very small portion of our business. We believe that the final rule, which provides for an approximately 2% increase in reimbursement is a good indication of the continued value placed on homecare services for end of life care.

Overall, we believe that the reimbursement environment continues to be positive and should create tailwind for the industry in 2022 and beyond this brings to mind, what we believe is a significant advantage for avianca.

Across all payers, including Medicare 36 unique state Medicaid system and hundreds of managed care plans Avianca has no single payment source that represents more than approximately 11% of our overall revenues.

This dynamic gives us great comfort in any downside scenario, but in the meantime, the horizon is clear and the homecare industry appears to be solidifying its relevance in the healthcare continuum.

Turning now to another significant event for the company in July of this year, we completed the refinancing of our remaining debt of $860 million, which significantly reduces the cost of capital for the company going forward.

In addition, we put in place a $200 million.

Revolving credit facility, which remains undrawn as well as the delayed draw term loan for another 200 million for future M&A.

Dave will provide more details related to the refinancing during his comments in summary, this refinancing has significantly reduced interest expense, while providing access to capital to continue our aggressive acquisition strategy.

Barclays team led the financing along with our full syndicate, we'd like to say a special thank you to all of our lender partners for your continued support.

On the topic of M&A I would also like to spend a moment updating you on our M&A activity. As a reminder, we closed on the Doctor's choice acquisition on April the 16th 2021 as a result, our Q2 numbers reflect approximately 10 weeks of doctor's choice activity.

Doctor's choice as a traditional Medicare certified home health business with 16 locations across the state of Florida.

At the time of the acquisition the company was producing revenues of approximately $70 million on an annualized basis Dr.

Doctors choices continued its successful growth trajectory since closing and the integration of the business into our home health platform is tracking ahead of plan.

Our integration management office continues to exceed expectations, both on the quality of our diligence and transactions as well as the timeliness of integration, which gives me great confidence in our ability to identify close and integrate acquisitions at a pace that is consistent with our model.

So where are we with our M&A pipeline.

The deal flow remains robust and as a result, we have several deals at various stages of our process earlier. This year, we disclosed that our goal was to acquire between 150 and $200 million of revenue per year, moving forward with a heavier slant toward home health assets.

With the closing of Doctor's choice in April and the Revote the robust deal flow and the various deals that we are engaged with currently we are confident that we will meet and exceed our M&A goals for 'twenty, one and beyond.

This brings me to my final topic before I turn the call over to Jeff for a deeper dive into some of our operating metrics.

Recall that our previous guidance of revenues not less than $1.745 billion and adjusted EBITDA of not less than $185 million did not contain any future M&A.

While we are highly confident in our guidance and given the likelihood that we will have additional M&A activity to announce in the second half of 'twenty. One we will hold off on updating our guidance until that time.

I'd once again like to thank all of the employees for Avi on them and the work that you do each and every day to provide great service and exceptional care to our patients is what you do that makes these results possible with that Jeff why don't you provide some additional insight into our segment results.

Thank you Tony.

It brings me great pleasure to share our Q2.2021 operating indicators in key metrics with you.

As a reminder, I will comment on our three operating segments private duty services.

Health and in hospice and medical solutions.

Before I get into the operating segments I'd like to focus on our Covid 19 update and payer to payer and government relations efforts.

Throughout the Covid 19, pandemic I have been proud of our ASEAN, the team's dedication to providing safe and efficient healthcare and our patients' homes.

We have managed through the pandemic and have a well disciplined approach to the acquisition of PPE.

Explanations of our staff.

Testing and tracking Covid positive cases, with staff and patients and effectively managing our business in a covid environment.

We continue to monitor the Delta variant and its impact on our communities, but feel we are well positioned to meet the growing needs of our patients referral sources and payors.

On a government and payer relations front, we are very pleased with our efforts and those of our state legislative and government agencies.

We believe that our homecare message is resonating with our key payer and government constituents through reimbursement rate increases and the expansion of covered services.

We also anticipate realizing additional benefits with the <unk> funds as states submit their plans to CMS for approval.

We have further aligned our avianca and homecare industry efforts on return to work initiatives.

A key component of our growth is focused on accelerating caregivers back into the workforce.

We have found our state governments willing to partner with us to provide an appropriate transition from unemployment benefits back to meaningful employment.

As most states are phasing down unemployment benefits. This summer we are experiencing a renewed interest from our caregivers to reenter the workforce and get back to providing high quality care in the home.

In summary.

Our payer and government relations teams have been instrumental in many rate wins expansion of coverage services and supporting the return to work initiatives.

Now onto the private duty services segment results.

During Q2, we produced $349.7 million of revenue or 11, 3% year over year growth.

Revenue was driven by 992 million hours of care provided during the quarter or 10, 1% growth over Q2 of 2020.

This growth rate is consistent with our strategy to grow Pds with both organic and M&A activity.

We expect to continue to see solid pds volume growth rates throughout 2021.

Our revenue per hour of $35.25 was up 39 from Q2 of 2020.

This was primarily driven by reimbursement rate improvements and stabilization of our business mix between skilled and unskilled services.

We continue to anticipate that this rate trend will improve in the second half of 2021 with the expected return of schools in the fall.

Turning to our cost of labor and gross margin metrics. We continue to experience improvement in gross margin was $105.8 million in Q2 or 33%.

This equates to a growth of 17, 4% year over year and gross margin dollars.

Gross margin improvement was driven by our Pds cost per hour of $24.59.

Down 27 cents per hour from Q2 of 2020.

Private duty services cost per hour is benefiting from the unskilled mixed shift and strong labor oversight.

Lastly, our spread per hour and important metric balancing revenue and labor cost for the private duty services segment improved to $10.66 per hour.

Fred per hour, we will continue to improve as we balanced the numerous rate increases against our strategic investments and caregiver wages and an effort to accelerate the growth of our Pds business.

As we.

Because in Q1, we expect our school private duty nursing business to return to an in person setting this fall.

Most of our school business typically returns by Labor day, and is a key component in higher acuity skilled nursing volumes as.

As well as providing the necessary childcare for our nurses to return to work full time.

We are encouraged by the commitment of our school systems to provide a safe and rewarding environment for our patients and caregivers to thriving.

Lastly, our Pds teams have fought diligently through the pandemic to continue to bring families home from the picky in NICU setting to the comfort of their homes. Many for the first time ever.

I am in all of our <unk> team's commitment to our families to providing high quality cost effective and compassionate care.

Now moving on to our home health and Hospice segment for Q2, where we continued to experience substantial growth.

With the addition of Doctor's choice home health or home Health and Hospice Division has expanded to 11, 5% of our Q2 revenue.

Home health and hospice continues to be a significant focus of our future growth and has been a point of emphasis for us as we work to expand our national home health presence.

Home health derives approximately 95% of the revenues of the home health and hospice segment and as our key focus moving forward.

With the five points and recover health integrations complete we are efficiently moving through the doctor's choice integration.

Our dedicated <unk> office is leading the way as we methodically integrate doctors into the Avi on our home health and hospice family.

I believe doctors will be one of the best acquisitions, we have completed to date and will act as a model we emulate as we move forward in our home health and hospice M&A strategy.

Now onto home health and hospice segment indicators for Q2.2021.

This is our second full quarter reporting home health and hospice metrics. Therefore, we plan to report sequential quarterly growth throughout the remainder of 2021.

During the quarter, we produced $51 million in revenue, a 59% increase over Q1.2021.

This was driven by 11700 total emissions approximately 61% being episodic admissions and 10300 total episodes of care.

Episodic admissions grew 87% while total episodes of care grew 81% over Q1.2021, primarily due to the impact of Doctor's choice acquisition and a strong organic growth from the recover health and five points businesses.

I am pleased with the organic growth rates of our home health business and believe we will remain a double digit admission growth segment for the remainder of 2021.

Lastly revenue per episode for Q2 was $2894 per episode and in line with our expectations.

From a cost and margin perspective gross margins were $80.48, 5% for the quarter up 350 basis points from Q1.2021.

The primary driver of gross margin improvement was the doctor's choice business along with the continued focus on payer mix.

Our home health and Hospice Division team is complete and actively implementing the best practices from all three acquired businesses.

I have great confidence in our continued execution of the business and its overall growth impact on aviano.

Lastly, we are pleased with the recent home health and hospice proposed and final rules and rate improvements for fiscal year 2022.

We believe that Avi on our home health and hospice is well positioned to capitalize on the ever evolving home health landscape as we look forward to partnering with our payers referral sources and CMS on value based strategies.

Now to our ASEAN, a medical solutions segment results for Q2 on.

Our medical solutions business provides enteral nutrition and other medical supplies directly to patients' homes.

During Q2, we produced $36.4 million of revenue or 11, 1% year over year growth.

Revenue was driven by 78000 unique patients served during the quarter or five 4% year over year volume growth.

Although we had a very strong unique patient serve comparable from Q2.2020, I am proud of the six 8% sequential growth EPS growth over Q1 of 2021.

This growth profile is consistent with our strategy to grow medical solutions with both strong organic and de novo activities.

We are currently servicing over 26000 patients per month, and our medical solutions business with plenty of geography for continued growth.

Our revenue per <unk> was $466.17.

Up five 7% from Q2, 2020, primarily driven by product mix shift.

I expect both volume growth and revenue to continue to benefit from the growth of our Pds and home health and hospice segments.

On the payer front.

We've had some recent medical solutions Medicaid rate wins tied to our overall payer strategy.

We also recently renegotiated a national medical solutions contract that will allow us to expand to all states, we serve and access a greater patient base. However, at a lower revenue per UBS.

In concert with this change we are leveraging improved cost of goods and reducing overhead to maintain margins in line with our medical solutions business model.

Turning to cost of goods and gross margin metrics, we continue to experience great stability in gross margins was $16.5 million in Q2 or 45, 4%.

This equates to a year over year growth of 90 basis points in gross margin percentage.

Gross margin improvement was driven by product mix shift and overall efficiencies in our delivery model.

Expect gross margins to remain in the 44% to 45% range.

I am proud of our medical solutions team and Theyre demonstrated ability to scale the interim nutrition business on a national basis.

In summary, all three aviano business segments have been performing at or above expectations.

As we continue throughout 2021, we are well positioned for organic and acquired growth.

Efficient margin controls and excellence and clinical outcomes.

Value based reimbursement strategies and customer satisfaction.

I look forward to updating you again at the end of Q3 on our continued progress with that I'd like to turn the call over to David <unk>, Our CFO Dave.

Thank you Jeff I will go ahead and provide some more details on results of operations adjusted EBITDA liquidity.

<unk> events in Q2, and Q3 and 2021 guidance.

Tony said earlier revenue was $436.1 million for Q2 of 2021 as compared to $351.6 million for Q2 of 2020, an increase of $84.5 million or 24%.

This increase was driven by growth across our key segments, including a $35.5 million or 11, 3% increase in Pds revenue.

A $45.4 million or 975% increase in home health and hospice revenue.

And a $3.6 million or 11, 1% increase in medical solutions revenue.

We're pleased with our overall volume growth, particularly from the home health and Hospice segment and our most recent acquisition Doctor's choice, which is a great acquisition for us.

With respect to rate our Pds revenue rate increased one 2% on balance due to the rate increases mentioned earlier net of the change in business mix between skilled and unskilled services.

We view the Pds reimbursement rate environment as a tailwind for all the reasons, we talked about earlier.

Revenue rate in our medical solutions business also increased five 7% from the year ago quarter.

Before turning to gross margin I'd like to quickly highlight the revenue impact of the Doctor's choice acquisition.

Avi on our revenues for the first six months of 2021 were $853.3 million, an increase of $146.5 million or 27% from the first six months of 2020.

Including Doctor's choice revenue of $22.9 million for the period in 2021 prior to when we acquired doctors pro forma Aviano revenue for the first six months of 2021 would have been $876.2 million, which represents a 24% increase over the first six months of 2020.

Now turning to gross margin our gross margin was $146.6 million or 33, 6% of revenue for Q2 of 2021 as compared to $106.6 million or 33% of revenue for Q2 of 2020.

The 37, 5% growth in our Q2 gross margin compares favorably to our revenue growth of 24% from the year ago quarter.

We are very happy with the consistency and stability of the gross margin percentages that our Pts segment has delivered over time, which have increased recently in our quarter over quarter and year to date comparable periods.

I want to emphasize that on a consolidated basis, our gross margin percentage increased 330 basis points in the current quarter as compared to the year ago quarter. As a result of a number of factors, including the higher gross margins delivered by our home health and hospice segment.

The rate increases we've received in our Pts segment and also a reduction in covid related compensation costs in the current quarter as compared to the year ago quarter.

Operating income was $30.3 million for the second quarter of 2021, or six 9% of revenue as compared to an operating loss of 52 million for Q2 of 2020, an increase of $82.3 million bear in mind that the driver of the operating loss last year was a $75.7 million goodwill impairment charge.

Orange that we recorded in Q2 of 2020.

Operating income for Q2 of 2021 was positively impacted by an increase of $17.4 million or 33, 7% and field contribution as compared to Q2 of 2020 to $17.4 million increase in fuel contribution was delivered by our $84.5 million or 24% increase in consolidated.

<unk> revenue combined with a 110 basis point improvement in our fuel contribution margin to 15, 8% for Q2 of 2021 from 14, 7% in the year ago quarter, which also represents sequential improvement from Q1 of 2021.

Fuel contribution in fuel contribution margin of our important metrics because they help us assess and make decisions about the operating performance of our core field operations prior to corporate and other costs not directly related to our field operations.

Offsetting some of the Q2 improvement in our field contribution margin over the prior year quarter was an increase in our corporate expenses as a percentage of revenue growing to seven 4% of revenue from six 5% of revenue in Q2 of 2020.

The primary reason for the 90 basis point increase was the $3.4 million corporate portion.

A $4.2 million in share based compensation charges that we recorded in Q2 related to performance vesting options as further discussed in the footnotes to our financial statements and our MD&A.

Note, however that adjusted corporate expenses as a percentage of revenue decreased to 5% in Q2 of 2021 compared to five 2% in Q2 of 2020.

Wrapping up with operating income operating income as a percentage of revenue improved to six 9% in Q2 of 'twenty one from a loss of 14, 8% of revenue in the year ago quarter.

Moving on to net income net income was $1.3 million for Q2 of 2021, an increase of $78.8 million for Q2 of 2020 with the primary driver of the increase again being a $75.7 million goodwill impairment charge that we recorded in Q2 of 2020 as I mentioned earlier.

Adjusted EBITDA was $48.8 million for Q2 of 2021, which represents $5.1 million a sequential growth from Q1 of 2021, and an $11.4 million increase from Q2 of 2020, we were pleased to see expansion in our adjusted EBITDA margins from 10, 6% in Q2 of 2020 to 11.

2% in Q2 of 2021 is the quality of our adjusted EBITDA continues to improve.

On a year to date basis, adjusted EBITDA increased to $92.6 million for the six months ended Q2, which represents a 10, 9% margin from $67.2 million in the first six months of 2020 or nine 5% margin.

On the liquidity front, we had very strong liquidity as of July <unk> 2021, with cash on the balance sheet of $107 million and available borrowing capacity under our revolving credit facility of $180 million, resulting in total liquidity of $287 million at the end of the quarter.

And this is after returning $29.4 million of provider relief and stimulus funds to federal and state agencies in Q1 of 2021.

With respect to our cash collections and DSO. Our DSO was 41 six days for Q2 of 2021 as compared to 39 eight days for Q2 of 2020, we expect our DSO to increase over time as we grow our home health and hospice business as those businesses businesses generally have longer collection cycles.

With that said our revenue cycle and operations team worked tirelessly to collect every dollar we're entitled to receive and we continue to make improvements every day to what we do.

Excellence in cash collections as one of our five CS and we work hard at it every day.

One of the results of that hard work is an improvement in revenue realization that we've seen across our comparable year to date periods I can't say, how pleased I am with the collaborative nature and all the hard work that our revenue cycle and operations teams put into collections everyday.

Capital expenditures for the first six months of 2021 were 0.7% of revenue as compared to one 5% of revenue in the first six months of 2020.

We typically view our capex in a range of one to one 2% of revenue.

Our capex in the first six months of 2020 was lower than normal due to the deferral of various projects, which we expect to incur in the future and was higher than normal in the first half of 2020 due to a data center project, we completed during that time.

And before we finished with our liquidity discussion I also want to cover our recent amendment to our credit facility that Tony mentioned earlier, and which significantly reduced our debt service costs and provides for incremental acquisition financing capacity.

As you recall in May we repaid $307 million of second lien debt, which allowed us to terminate our second lien facility and also repaid $100 million of first lien debt all with proceeds from the IPO than.

And then on July 15th we refinanced our remaining outstanding first lien term loans combining them into a new seven year first lien term loan.

You will see this described in our documents as the 2021.

Extended term loan.

Combining the three former first lien loans, all of which had different interest rates into one new term loan simplifies our loan structure and we also reduced our interest rate under the new term loan to LIBOR, plus 375% with a LIBOR floor of a half a percent.

Youll see a table in our press release that provides these calculations and holding all other factors. The same based on current interest rates, we expect to save $13 million in annual cash interest on our outstanding $860 million first lien term loan as a result of this refinancing and I want to emphasize that that doesn't include the cash interest savings will realize as a result of our.

Debt Paydown with IPO proceeds, which will drive further cash interest savings as compared to the cash interest paid that you see in the first six months of 2021.

If you look at our cash interest trend our cash paid for interest in Q1 of this year was $20 million, which decreased to $16 million in Q2, and which will continue to decrease in Q3.

On July 15th we also added a $200 million delayed draw term loan to provide for future acquisition financing, we incur no interest on undrawn amounts of the delayed draw term loan for 45 days. After the July 15th Amendment date.

Then for the next 45 days, we pay interest at 50% of our LIBOR margin rate and then we incur the full LIBOR margin beginning at 90 days, which would be on or about October 15.

And turning to our full year 2021 guidance, we are affirming our expectation that revenue will be at least $4.74 5 billion.

We're also affirming our expectation that adjusted EBITDA will be at least $185 million and for the reasons outlined in the press release, we are not providing guidance at this time on net income.

To summarize and wrap up here. We're pleased to have continued our positive earnings momentum in Q2 with the capital structure improvement we've achieved through pay down of debt with IPO proceeds and the subsequent refinancing of our credit facility in July to reduce cash interest cost, we expect to drive improved operating cash flow in the future we are well positioned.

<unk> from a liquidity and credit perspective to execute on future M&A and look forward to all the opportunities in front of Avianca.

And with that operator, we're ready to open up the call for questions.

And at this time, we will be conducting a question and answer session. If you'd like to ask a question. Please press star one on your telephone keypad.

Information tone will indicate your line is in the question queue.

You May press Star two if you would like to remove your question from the queue.

For participants using speaker equipment, it may be necessary to pick up your handset before pressing the star keys.

We also accident each participant limit themselves to only one question and one follow up question due to the high volume of questions in the queue.

One moment, please while we pull for questions.

And our first question is from Matt Borsch with BMO capital markets. Please proceed with your questions.

Yes, I was hoping maybe you could talk a little bit more about the environment for labor.

Labor recruitment and retention.

Gaslog recruitment retention and the various areas of the business.

Some other companies have struggled with that.

Just wondering.

Get to which you.

Mike.

Pressures in any area on that front.

Potential wage pressures in particular.

Well first of all thank you for the question Matt ill.

I'll start and then Jeff why don't you jump in I guess, what I'd like to do is go back prior to the pandemic.

We are in the business of recruiting nurses and recruiting nurses has always been difficult. So there are not enough nurses to meet the demand of our growing seniors the medically fragile children population and so we live in an environment, where we're this is the reality that we have now with that said depending.

<unk> has made it harder.

But I'll give our team credit.

We have some innovative ideas that Jeff and the operating team had been working on which I think are our.

Street, leading but Jeff why don't you give them a little bit of color about some of the initiatives that we have.

This is the success we've been having yes, thanks, John Hey, Matt Good morning, Yes, as Tony mentioned, Matt.

We just had to become more creative innovative and flexible in our recruiting.

Patterns are.

I'll give it to our the.

Ahead of our recruitment and our Pds clinical operations teams. They are in Im sorry introduced a virtual based.

Orientation hiring process, all the way up to the.

The day before we put a nurse into a home being a branch and so we've just had to flex and become more innovative in this environment.

I think I think we fully understand the labor pressures and we see it there's certainly less nurses applying for more jobs on the front end, but it just made us become have to become better more innovative more flexible honestly more flexible in nature and I think as we talked about.

We turned our payer and government relations team is really focused on on getting the right wins that we can strategically invest back into the caregivers.

As Tony mentioned 16 state rate wins, and we are strategically investing that money back into both the recruitment of new nurses, but also the retention of our current nurses and so we expect that to continue.

We as we play throughout the rest of 2021 and into 2022.

And if I could ask a follow up on that just as you look out over the next few years.

How do you see the.

The supply and availability trends or is it just going to get it.

Get a bit tougher here.

Given some of the demographics and retirements.

Yeah, So Matt I don't I don't think Theres any kind of silver bullet in front of US. This is the nursing shortage is going to be resolved I think now.

Now granted as the pandemic subsides as as <unk>.

<unk> go back into the work of a matter of fact, not just nurses, but everybody goes back into the workforce I think I think things will level out a little bit, but if you go back for the last 15 years. There has not been enough nurses to take care of the patients Theres 10000 people turning 65 every day the demand for our <unk>.

Services is going to continue to increase so I think companies are going to have to learn how to be creative innovative with how we approach people.

And how we pay people and how we recruit and onboard them I will tell you Jeff mentioned it. These guys I think have done a great job with some of the creative solutions about being able to recruit and onboard nurses conveniently from the comfort of their homes Jeff.

Jeff you talk about how we pay people to daily pay.

That's 10 years ago, we would've never thought about paying people on a daily basis and.

I think companies, including <unk> are going to have to continue to be creative and innovative in how we solve this problem because the problem is not going to go away.

Okay, great. Thank you.

Thanks, Matt.

And our next question is from Lisa Gill with J P. Morgan. Please proceed with your question.

Alright, thanks, very much and thank you for taking my question.

Can you comment.

Yes.

Value based care.

Thank you.

And from that perspective, do you have contracts in place around that.

Sure.

The outlook for that number one and number two.

I think the reimbursement work, Eric when you think about taking some element of risk and those contracts.

Yeah.

So first of all thanks for the question Lisa and today, if you think about back to 22021.

CMS was working with value based reimbursement and roughly seven states. We were participating in two of those so we are very comfortable with the process.

We have had success in the two states that we're operating in and we applaud CMS for moving forward with value based pricing we believe.

That companies should be.

Rewarded for the clinical care that we deliver and we're going to continue to focus on making sure that our care is delivered at the highest standard and we believe that the recognition that.

You are willing to pay more for great outcomes is something that we think is good for the industry. So we are very supportive of moving forward and taking risk where appropriate.

Tony when I think of that.

Pain for a better outcome.

Hi.

Opportunities for you downside too and then secondly, when you think about the Q D. How are they measuring the outcome and I just wonder with more of a pilot program do you think that's all rolled out more holistically as we get into 'twenty two.

Okay.

<unk>.

I think you asked there was three or four different questions. Here I think the answer is yes. We are equally we are equally excited about the opportunity for upside in reimbursement, but we also.

Are accepting of the risk of downside and so.

I think I think that companies are going to have to get comfortable with taking that risk.

Unless they perform reimbursement can go down now we look at it.

The glass is half full thing we have the opportunity to be paid for the extra effort that we do and I think we will enjoy some success under that program.

Okay, great. Thanks.

Thanks Lisa.

And our next question is from a J Rice with credit Suisse. Please proceed with your question.

Thanks, Hi, everybody first of all just to follow up on your comments about pricing in 2016 covered states, where you get rate increases I wondered a is there are there any big states that still remain open and can.

Can you give us sort of a sense of the blended average rate increase you think youll see it.

And the Pds business heading into next year, and maybe what timeframe those.

Rate increases roll through the numbers.

So Jeff.

I'll start and then why don't you jump in and give them a little color around the aetna.

Program.

Jay as you know, we don't disclose any state specific information. So so we'll be we'll tread lightly here. If you think if you think about our top seven states, where we have a lot of volume in the top seven states, we've experienced either rate increases and or <unk>.

Spansion or benefits in roughly five of our top seven states. So so it's not the rate increases that I referenced are not only related to states, where we have small pieces of business, but really across the board. We have we have small states large states medium states everybody is has participated.

And I'll tell you I would go back and give Jeff and the team.

Our government and payer relations team they've done an exceptional job during a pretty difficult environment of getting out in front of our constituents and showing that we can be a part of the solution not a part of the problem and I think.

I feel like our states are looking toward us to help them solve this issue and getting these patients out of the hospital. So with that Jeff why don't you give a little bit of color around some of the specific program and a J I think as Tony said it normally by now we would really be done for the year.

All of our states had finished there.

Either annual or biannual legislative processes, and so normally we would be starting to focus on 2022.

This year is uniquely different and the fact that most states have yet to submit their aetna that plans to the to CMS and are doing so over the next few months. So we've already pivoted from the normal annual biannual legislative process that we talked about with the 16 wins and now we're immediately going back and meeting with our states.

As theyre going back and many of our going back into session to figure out how they will spend their money.

They are proposals will be and so I think we feel very very bullish that we're going to go win some additional rates through the aetna process and I think as Tony talked about it's not just winning rates. It's really it's really strategically helping the state's invest that money back into caregivers retention development clinical oriented kind of orientations.

System. So I think we will see additional rate wins throughout the second half of 2021 going into 2022 that were that were never contemplated and Jeff you said it in.

For a J as benefit you said it in your prepared remarks, one of the things that I think is so important when we look at these rate wins.

<unk> by state, we're not seeing this as it is improved profitability. What we're seeing is the ability to take those resources and reinvest those strategically back into the caregivers and by doing that we'll be able to bring more caregivers back to the workforce and I think ultimately the IND.

<unk> wins, and I think it will accelerate growth in our industry.

I believe our industry is experiencing today is a little bit of a slowdown because we just got we got to get people back to work and I think the states recognize that and all through the state Medicaid systems and Fortunately they can actually move a little bit quicker than some of our federal program scan and they can put dollars back into the <unk>.

Under the program to bring workers back industry will ultimately will cause.

Our growth rates to accelerate.

Okay. Maybe just my follow up then would be you mentioned the choose home and we're hearing others comment about what that could mean and other legislation around the infrastructure package, perhaps helping.

The bigger infrastructure package that goes anywhere off perhaps helping on the.

Personal care side.

How are you thinking about these and would you pivot on your strategy in any way if.

Any of this gets passed.

I don't I don't let me I'll take your last question first I don't think we pivot at all I think.

I think all of the activity Youre seeing in D. C. Right now is consistent with our strategy. So I think we just move forward.

But Jay you asked about.

How do we feel about it and what's the likelihood of it passing and look your.

Your guess of what's going to happen in D. C is as good as mine.

Things are in the Senate has got to go to the house Gotta get approval.

I don't know what the outcome is going to be in.

And quite frankly, what's most important to me where I do see a lot of value is that people in D. C are talking about homecare and homecare being a part of the solution. So whether this bill is passed or that bill is passed or this it has this amendment or it doesn't have this amendment.

I think what is most positive for the industry is that debt.

That our leaders on a federal level as well as on a state level and the Medicaid system are recognizing the value that homecare can play and are seeing the homecare is a is a value add to the overall healthcare spend that's what I find so positive.

Okay, great. Thanks, a lot.

Thanks Ajay.

Yeah.

And our next question is from Sarah James with Barclays. Please proceed with your question.

Thank you and congrats on a strong quarter.

On recruitment and retention has been an area of strength driving above.

Average growth rate for you guys. I know you have the strong rate environment, maybe some funding expansion I was hoping you can give us some insight into how sensitive recruitment and retention to wage increases. So do you have any examples in markets, where you've seen a correlation.

Tween.

Hourly wages and what's going on on the recruitment side.

Then if you can walk us through any non wage related items that youre working on for either recruitment or labor efficiency.

Okay.

Sara Thanks for the question and.

The example, I will throw out to you is a little bit dated.

Had a relatively large rate increase in the state of California.

In 2018 to us and immediately after the after the rate increase went into place we saw an acceleration of our growth rate because clinicians came back to work.

We were able to pass on a fair amount of that debt.

Right.

We reinvested that back into our wages for our clinicians and the result is which we saw an increase in staff hours, which all and also an increase in admissions which means.

I think California was pretty smart about it.

Had the desired impact it caused patients to get out of the hospital sooner and and I think.

I think we will see that play through through all of these states that have made the decision to reinvest back into the business. So so with rate comes growth and and we can and we've demonstrated that time and time again now with that said one of the things that really if you think about where we are in our bid.

Today, the summertime tends to be our slowest season of the year, we have nurses on vacation, we have schools out of service and so one of the things that we've talked about is it.

We anticipate schools being back in session in full swing this year and that will help lift our rates as well, but Jeff why don't you provide some color for Sarah as to how the school systems swing our business. Thanks, Tony and good morning, Sarah I think Tony said it well Sir this is we're on the eve of our schools going back in to in person.

And we are monitoring it very closely with the Delta variant proud to say every school then every school district that we currently service is planning to be either in person is either gone back or is going back over the next three weeks. We're monitoring that every week to make sure that that continues in a safe and effective manner.

But as Tony talked about it's an important it's an important on recruitment tool for us. It's an important step for us as many of our caregivers are also parents and their kids are home they've got to have some kind of child care daycare and so.

The in person school setting is a big step for us to get back back in the falling in to get that workforce back to work and I think as Tony talked about we've now got some incremental dollars to go strategically back and invest in those and make the make the wage rates more appealing to those nurses to come back in the workforce and I think as we said earlier, we have found our state legislators to.

Incredibly understanding and focused on getting people back to work and I think we have found that to be very refreshing that theyre not fighting against the idea of getting their concessions back to work. They they really do want unemployment will ramp back down and to help people get back into meaningful employment and I think we're a great a great market and a great opportunity for that to happen.

Thank you and just a follow up I know this isn't the weed so happy to follow up off line, but backing that California example in 2018.

Do you have any.

Numbers that can help us frame up what the result.

Our volume months.

Yes.

We'd be happy to talk to you know take that offline and walk you back through that.

But I think as Tony said, it's a great example of how we strategically invest at a 30000 foot we didn't keep that money and just and just increased margins. We we strategically invested that in it of caregivers over a multiyear period to really effectively do it but the <unk>.

California, legislated wanted which was to go staff more cases.

Thanks Sarah.

And our next question is from Joanna.

Bank of America. Please proceed with your question.

Hi, guys. Thanks for taking the question. This is actually a corn you found you pay on for Joanna.

I guess just one one on the on the deal pipeline I mean, you guys called out that you know the pipeline remains robust and you've reiterated that you'd be able to hit your acquired revenue target for the year, which is great.

But just curious are you seeing are you seeing multiples increase for home health and hospice assets could you mentioned that.

M&A is really going to skew in that direction and just wondering you know are you seeing increased competition for these assets.

Well. Thank you for the question and going back to our pipeline on any given day, we have over $600 million of transactions in our pipeline and I'll I'll remind you that we have a very disciplined process.

We pass on more deals certainly on a lot more deals than we do.

And so we're very selective as to the as to the deals that we do.

And from a competitive perspective, yes.

Some of our deals we've been able to do.

Kind of as a one off transaction and others are highly competitive but going back to the size of the pipeline compared to the number of deals we do when we identify.

<unk> and it is a good fit for our company and it's a well run company and we know that integration is going to be straightforward and we know that we're going to be able to realize the synergies.

Even in a competitive environment. When we decide that this is a transaction we're going to do we're going to close that transaction and I think if you if you.

If you go back to our chairman leads that effort and.

And he's got close to 40 years' experience in the homecare space and doing transactions and.

And I'll use doctors choices. Our most recent example, doctor's choice as Jeff said I think it's going to go down as one of the best transactions that we've done and that was a highly competitive process, but we bring synergies to the table and we have a very disciplined approach of how we get to those synergies so because of that when we need when we need to increase what we.

We will do that because over the long run that will end up being a very cost effective transactions. So.

Yes, it's a competitive process however.

I think we've got that.

The capital the infrastructure of the <unk> team that I think we can we are we need to we can we can be successful.

Okay. Thanks, that's Super helpful. And then I think that's a good segue into my follow up on Doctor's choice. You guys mentioned, it's tracking ahead of expectation in terms of time, we ask that you know it's one of the best acquisition to date. The team could you just give a little bit more color on the integration I'd like the specific synergies youre seeing that are making you feel that way.

Well.

I'll go back and make it as it is I think it is going to be one of the better transactions. The Premier health transaction that we did in 2018 was a very good transaction. It was more on the private duty side. This is doctors choices all on the on the home health side.

They are all equally good and we've found the.

Deliver a quality product within the company.

They've got good market penetration across the state of Florida, which is highly desirable state related to seniors and so.

Thank you.

I, just I think it's going to be a great great transactions for us now with the synergies we don't we haven't disclosed specifically what the synergy that that transaction is going to be.

But when you think about the comment that I had made earlier, we have a highly leverage able infrastructure when I think about our corporate spin, which includes HR and payroll and accounting and finance and tax.

<unk>.

Recruitment infrastructure and some billing and collecting in those those are all highly leverage able.

Services, so when we look at doing an acquisition.

Where there is duplicative payroll and accounting and finance and executives, we were able to get very aggressive and doctors is no exception to that so.

We won't have any concern at all achieving all of the synergies related to doctors.

Alright, great. Thanks, Tony.

Thanks Courtney.

Yes.

Our next question is from Peter Chickering with Deutsche Bank. Please proceed with your question.

Hey, Good morning, guys couple of quick questions here for home health can you give us any color on what the pro forma organic growth rate was obviously almost all the growth in the quarter is due to M&A from year over year perspective, but it would be helpful to track.

<unk> growth rate was from those acquisitions and assuming no more deals closed except for a little more from.

Revenue from Doctor's choice some color on how home health revenue should track sort of throughout the back of the year.

Yeah. Peter this is Jeff good morning.

I think it is it in our prepared remarks, even though we did not own obviously, both recover and five points. This time last year.

Using their systems year over year, we're really pleased I mean were in line with the industry in that double digit growth rates, specifically the admission growth rate.

<unk> continued to be a primary episodic growth focused business.

And I'm, just really pleased with both both of those businesses.

As we've taken them through integration from Q4 of 2020 wrapping up integration in Q2 of 2000.22021 of this year those businesses are both growing in excess of 10% and showing double digit and Tony just said on <unk> last question one of the things we love about doctors as it's growing through the integration.

It's got great density.

It's got a great market presence in Florida, and it's growing double digits as well and so I think we're pleased with our business development effort.

We have labor pressures in the home health business that theyre not as intense as the Pts segment, but our number one focus in home health right. Now is just is recruiting and retaining more nurses. So it's a similar focus but to answer your question double digit organic admission growth pretty consistent throughout all three of the former former companies alright perfect.

And then actually a follow up to <unk> question that I have two quick modeling questions after that one but yes.

We've seen the public company home health multiples compress pretty substantially this year, just curious how does it impact the private markets.

Sellers adjust expectations or the deals pause a bit as we have this disconnect between lower public company valuations and maybe some high private company expectations.

I don't think the market I don't think the market has paused and we're seeing as much deal flow today as we saw a year ago and in some circumstances I think it's even higher and now you and I can pontificate about why do we think that is I mean, theres a lot of rattling about.

Changing a capital gains taxes, and such that May cause.

Someone who might have been a seller before just maybe take a stronger look at it today.

So.

The pipeline is robust and I think we will continue to be that way I think over time I think the lower valuations for some of the public peers will find its way into deals down the road and sellers may have to adjust our expectations, but for the time being I'm not seeing we're not seeing any compression at all.

Okay, and then David just Super quick follow up questions.

What does the pro forma.

Quarterly run rate of interest costs going forward and then on SG&A margins. It sounds like you have taken this quarter to the options as you can.

SG&A as a percent of revenue as the back half of the year, just any color on whether it's a truck. Thanks so much.

Yeah.

Thanks, Peter for the question. So I mean, what we've what we've disclosed in our press release, you can see is that.

We're going to save $13 million annually holding all other factors constant between what we're incurring on our term debt.

Immediately prior to the transaction to immediately after if you think about the annual $36.37 million interest that will occur on that incur on our extended term loan. There is a couple of other things that would roll into that related to unused undrawn fees on our revolver.

Fees that we incur on our Lcs and some other things in addition to amortization of deferred financing costs. So if you roll all that up you might see GAAP interest expense in the <unk> $41 million to $42 million range.

But that also does not include any interest on the delayed draw term loan that we talked about.

We'll just see where that goes with respect to our M&A activity.

Thanks Peter.

Okay.

And our final question comes from Brian <unk> with Jefferies. Please proceed with your question.

Hey, good morning, guys.

One question for you so as we think about Covid and the resurgence that we're seeing.

Maybe if you can share with us kind of like what your experience was last year.

How does that impact your business and your patients in terms of your ability to or their willingness to let you in the door and just curious just so that we can figure out how to think about covid and how it impacts you going forward. Thanks.

So Jeff I'll start and then you just jump in.

I think some color around what patients are saying.

It matters.

Brian at the lowest point last year, our volumes were off about 10% and and so.

That is call. It April may of last year, we've seen an improvement throughout the rest of 2020, we're seeing that volumes decline again related now related to the two the delta variant.

And the experience there, but I think maybe unlike a year ago, where maybe some of our families kind of pull back a little bit I think our families have grown accustomed to offer two living and taken care of children in the home with Covid, but Jeff why don't you provide some color for Brian about what we're hearing from families.

Yes, well said Brian.

In the home environment, where we put one nursery with one patient in the home I think we're still very well protected and as Tony said.

None of our patients haven't haven't heard with and dealt with with Covid now for over a year.

Delta Varian has our attention has all of our all of our health providers attentions.

We're monitoring appropriately I don't think its going to have a long term impact or significant impact on how our families feel about having the nurse in their home I think the nurse likes that one on one setting the family understands its one or two nurses I think our families are really focused on keeping them out of the hospital. So that families don't want to go back into the hospital for emerge.

Revisit they never do but they certainly don't don't right now.

And I think as we said our pivot to schools were really partnering I give our schools credit our school leaders credit, they're really trying to be thoughtful on how they can do in person. They know how important that is for the kids and it just it just rolls downhill to us it's really an important aspect of maintaining that through the delta variant.

I think our school systems.

Have been very thoughtful about how they how they're how they're planning on doing it this fall.

Awesome. Thank you guys.

Thanks, Brian I appreciate it.

And we have reached the end of the question and answer session I'll now turn the call over to Tony Strange for closing remarks.

Thanks, Operator and again, thank you for your interest in the <unk> story, we look forward to updating you on our continued progress as we go and operator that concludes our call.

And this concludes today's conference and you may disconnect. Your lines at this time. Thank you for your participation.

[music].

Yes.

Yeah.

Yes.

[music].

Yeah.

Yes.

Okay.

[music].

Okay.

Yeah.

[music].

Okay.

[music].

Okay.

[music].

Okay.

[music].

Okay.

<unk>.

Yes.

Okay.

Yes.

Thanks.

Okay.

[music].

Yeah.

[music].

Yes.

[music].

Sure.

Yes.

[music].

Okay.

[music].

Okay.

Yes.

Okay.

[music].

Okay.

[music].

Yes.

Sure.

[music].

Okay.

[music].

Okay.

Yes.

Okay.

Sure.

Okay.

[music].

Yes.

Okay.

Yes.

Okay.

Sure.

Okay.

Yes.

Okay.

Yes.

Okay.

Yes.

Okay.

Yes.

Okay.

Yes.

Okay.

Yes.

[music].

Okay.

[music].

Okay.

Yes.

Okay.

Right.

Yes.

Okay.

[music].

Okay.

[music].

Great.

Yes.

Sure.

Okay.

Yes.

Okay.

Hum.

Okay.

[music].

Hum.

Okay.

Yes.

Okay.

[music].

Yeah.

Yes.

Right.

Okay.

Yes.

Okay.

Yes.

Okay.

Sure.

Yes.

Okay.

Yes.

[music].

Yes.

Okay.

Yes.

Okay.

Good morning, and welcome to the Avianca healthcare Holdings' second quarter 2021 earnings Conference call.

Today's call is being recorded and we have allocated one hour for prepared remarks and Q&A.

At this time I'd like to turn the conference over to Shannon Dream, ASEAN, as Chief legal officer and corporate Secretary.

You may begin.

Thank you operator, good morning, everyone and thank you for joining Aviano healthcare second quarter 2021 earnings call speaking on today's call are Tony Strange I'll be honest, Chief Executive Officer, and President David <unk>, Our Chief Financial Officer, and Jeff Shiner, ASEAN as Chief operating officer.

Risks and uncertainties that could cause our actual results to materially differ from those expressed or implied on today's call listeners should not plan place undue reliance on forward looking statements and are encouraged to review our SEC filings for a more complete discussion of factors that could impact our results, including those risks disclosed under the risk factor headings of our filings.

Gov.

Following today's prepared remarks, we will open the call to questions. Please limit your initial comments to one question and one follow up so that we can accommodate as many callers as possible in the allotted time with that I will turn the call over to <unk>, Chief Executive Officer, President Tony Strange Tony.

Thanks, Shannon and good morning, everyone. Thank you for joining Avi honest second quarter earnings call before we get started I would like to welcome our new investors and say thank you for joining the Aviano story for our new participants Avi on it is a highly diversified homecare platform specializing in providing both skilled and unskilled care.

Two pediatric adult and senior patients in the most cost effective setting possible their homes. We operate in 30 states across the U S. Through 263 locations are clinical team focuses on providing exceptional position directed care to each of the 46000 patients that we serve.

Another successful quarter for <unk> as we continue to build on the momentum that we reported in Q1 revenues for the quarter were $436 million compared to $352 million in Q2 of 2020, representing a year over year increase of 24%.

And up sequentially from $417 million in Q1.

Moving on to gross margins gross margins for the quarter were 33, 6% compared to 33% in Q2 of 2020 and up sequentially from 31, 6% in Q1 of 'twenty one.

The improvements have been driven by rate improvements across our Pts segment, the mix shift driven by the growth in our home health and hospice segment and a disciplined approach to managing labor expenses.

Very proud of our operating teams for not only preserving but improving margins during a very difficult environment.

EBIT for the quarter was $49 million compared to $37 million in Q2 of 2020, an increase of 31% year over year adjusted earnings per diluted share for the quarter was <unk> <unk> compared to eight <unk> in Q1.

Great to have you on our team.

Moving on to the reimbursement environment.

The result is that over 50% of the states that we service will increase the reimbursement rate and or expand the covered benefit for the services that we provide.

To be specific.

We have or will receive rate increases in 16 of our covered states in 2021.

Jeff will provide some additional color on these increases during his comments, but the net takeaway is that state Medicaid agencies and managed care plans alike are recognizing the important role that homecare can play in reducing our overall healthcare spend.

These investments into the home care benefit will allow providers to make additional investments into caregiver wages, which should accelerate growth for the industry.

From a Medicare perspective, CMS has issued a proposed rule for home health in a final rule for hospice on the home Health front, we view the proposed rule as an overall positive for the industry.

It appears that providers will experience approximately a one 7% increase to reimbursement, but equally positive for us is the indication that CMS is moving forward with its commitment to evaluate value based pricing. There are several legislative efforts underway such as choose home.

To elevate the impact that homecare can play in helping post acute care patients transitioned back to their homes and allowing them to age in place.

This dynamic gives us great comfort in any downside scenario, but in the meantime, the horizon is clear and the homecare industry appears to be solidifying its relevance in the healthcare continuum.

In addition, we put in place a $200 million revolving.

Revolving credit facility, which remains undrawn as well as the delayed draw term loan for another 200 million for future M&A Dave.

Barclays team led the financing along with our full syndicate, we'd like to say a special thank you to all of our lender partners for your continued support.

Doctor's choice as a traditional Medicare certified home health business with 16 locations across the state of Florida.

At the time of the acquisition the company was producing revenues of approximately $70 million on an annualized basis Dr.

Doctors choices continued its successful growth trajectory since closing and the integration of the business into our home health platform is tracking ahead of plan.

So where are we with our M&A pipeline.

This brings me to my final topic before I turn the call over to Jeff for a deeper dive into some of our operating metrics.

Recall that our previous guidance of revenues not less than $1.745 billion and adjusted EBITDA of not less than $185 million did not contain any future M&A.

While we are highly confident in our guidance and given the likelihood that we will have additional M&A activity to announce in the second half of 'twenty, one we'll hold off on updating our guidance until that time.

Once again like to thank all of the employees for Avi on them and the work that you do each and every day to provide great service and exceptional care to our patients is what you do that makes these results possible with that Jeff why don't you provide some additional insight into our segment results.

Thank you Tony.

It brings me great pleasure to share our Q2.2021 operating indicators in key metrics with you.

As a reminder, I will comment on our three operating segments private duty services.

Health in hospice and medical solutions.